Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience.

Item

http://www.wikidata.org/entity/Q38848914

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Bevacizumab in the treatment o ...... trial evidence and experience.

@en

type

Item

label

Bevacizumab in the treatment o ...... trial evidence and experience.

@en

prefLabel

Bevacizumab in the treatment o ...... trial evidence and experience.

@en

P1476

Bevacizumab in the treatment o ...... trial evidence and experience.

@en

P2093

Fabrice Barlesi

http://www.w3.org/2001/XMLSchema#string

Laurent Greillier

http://www.w3.org/2001/XMLSchema#string

Pascale Tomasini

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 3.0 Unported

P2860

Hallmarks of Cancer: The Next Generation

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Tumor angiogenesis: therapeutic implications

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-s

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

P304

485-491

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1177/1753465816652083

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2016-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27340254

http://www.w3.org/2001/XMLSchema#string

P921

lung neoplasm

globulins

non-small-cell lung carcinoma

P932

5933613

http://www.w3.org/2001/XMLSchema#string